Cost-Effectiveness of Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Intermediate Risk: Results From the PARTNER 2 Trial

https://www.ctsnet.org/jans/cost-effectiveness-transcatheter-versus-surgical-aortic-valve-replacement-patients-severe?utm_source=iContact&utm_medium=email&utm_campaign=ctsnet&utm_content=JANS+12%2F21%2F2018


Cost-effective analysis of TAVR versus SAVR in 3110 intermediate-risk aortic stenosis patients from the PARTNER-2 trial

Costs were ~$20,000 higher with TAVR than SAVR.
Total cost differences for the index hospitalization were
only $2888 higher with XT-TAVR (p=0.014) and
$4155 lower with S3-TAVR (p<0 .001="" nbsp="" p="">owing to reductions in length of stay with TAVR.

Follow-up costs were significantly lower with XT-TAVR (△-$9304; p<0 .001="" and="" compared="" nbsp="" p="" s3-tavr="" savr.="" with="">
Over a lifetime horizon, TAVR was projected to lower total costs by $8000-$10,000 and to increase quality-adjusted survival by 0.15-0.27 years.

 XT-TAVR and S3-TAVR were found to be economically dominant compared with SAVR in 84% and 97% of bootstrap replicates, respectively.


Q
TAVR Durability is same as SAVR? We'll see.
If the durability of TAVR is inferior, the results might be changed.